COMP <GO>
RXRX vs VCEL // EV/EBITDA & P/E VALUATION
Recursion Pharmaceuticals Inc. (NASDAQ) VS. Vericel Corporation (NASDAQ) • 15-METRIC TALLY: RXRX 4
— VCEL 7
■ METRIC PARITY
LAST: $3.68 (-3.92%) • MKT CAP: $2.29B
valuation
—
LAST: $41.09 (+1.43%) • MKT CAP: $2.07B
valuation
61.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXRX VS. VCEL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXRX | VCEL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.00% | 74.40% | -69.40 | VCEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 3.40% | -38.40 | VCEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 61.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.95% | 1.13% | -16.08 | VCEL | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.00% | -64.00 | VCEL | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.00% | -66.00 | VCEL | /net-margins <GO> |
| Revenue Growth (YoY) | 26.90% | 16.50% | +10.40 | RXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.59 | 9.94 | -8.35 | VCEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | VCEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 47.7 | +0.10 | RXRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 111.7x | -79.70 | RXRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.29B | $2.07B | $211.7M | RXRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXRX REV | VCEL REV | RXRX GROSS % | VCEL GROSS % | RXRX FCF | VCEL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $74.7M | $276.3M | 5.0% | 74.4% | -$378.3M | $24.7M |
| FY 2024 | $58.8M | $237.2M | 23.1% | 72.6% | -$372.9M | -$5.8M |
| FY 2023 | $44.6M | $197.5M | — | — | -$289.8M | $35.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXRX // BETA 1.00
VCEL // BETA —